Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AP23573 · 1 trial · 3 indications
| Name | Type | Description |
|---|---|---|
| AP23573 | DRUG | ridaforolimus |
Inclusion Criteria (Patients must meet each of the following criteria to be eligible for participation in the trial): * Male or female patients ≥ 18 years of age * Patients must have a radiographically suspected progressive or recurrent primary malignant glioma (glioblastoma multiforme or gliosarco...
AP23573 is an investigational small molecule being studied for the treatment of malignant glioma, including glioblastoma and gliosarcoma. It was evaluated in a Phase 1 clinical trial in patients with progressive or recurrent glioma. The drug is not approved and remains in clinical development.
AP23573 is being developed by Merck & Company, Inc., which trades under the ticker symbol MRK. The company sponsored a Phase 1 clinical trial of the drug in patients with malignant glioma. Merck is the sole developer of AP23573.
AP23573 is in Phase 1 clinical development. A single Phase 1 trial of the drug has been completed in patients with progressive or recurrent glioma. The drug is investigational and has not been approved by regulatory authorities.
AP23573 has been studied in one clinical trial, identified as NCT00087451. This Phase 1 study, titled "Safety Study of AP23573 in Patients With Progressive or Recurrent Glioma (8669-023)", was completed in the United States and enrolled 11 participants aged 18 years and older.
AP23573 is the sole name provided for this investigational drug. No alternative names have been identified for this compound. It is being developed by Merck & Company, Inc. for the treatment of malignant glioma.